{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:15:48Z","timestamp":1748963748224},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"},{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/srep03644","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T10:12:19Z","timestamp":1389348739000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sensory-motor behavioral characterization of an animal model of Maroteaux-Lamy syndrome (or Mucopolysaccharidosis VI)"],"prefix":"10.1038","volume":"4","author":[{"given":"Paola","family":"Saccone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Cotugno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Mastrogiacomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Tessitore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Auricchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"De Leonibus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"BFsrep03644_CR1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1542\/peds.2006-2184","volume":"120","author":"R Giugliani","year":"2007","unstructured":"Giugliani, R., Harmatz, P. & Wraith, J. E. Management guidelines for mucopolysaccharidosis VI. Pediatrics 120, 405\u201318 (2007).","journal-title":"Pediatrics"},{"key":"BFsrep03644_CR2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1399-0004.1987.tb02779.x","volume":"31","author":"S Vestermark","year":"1987","unstructured":"Vestermark, S., Tonnesen, T., Andersen, M. S. & Guttler, F. Mental retardation in a patient with Maroteaux-Lamy. Clin Genet 31, 114\u20137 (1987).","journal-title":"Clin Genet"},{"key":"BFsrep03644_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-5-5","volume":"5","author":"V Valayannopoulos","year":"2010","unstructured":"Valayannopoulos, V., Nicely, H., Harmatz, P. & Turbeville, S. Mucopolysaccharidosis VI. Orphanet J Rare Dis 5, 5 (2010).","journal-title":"Orphanet J Rare Dis"},{"key":"BFsrep03644_CR4","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1203\/01.pdr.0000203090.41012.a6","volume":"59","author":"D Auclair","year":"2006","unstructured":"Auclair, D., Hein, L. K., Hopwood, J. J. & Byers, S. Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval. Pediatr Res 59, 538\u201343 (2006).","journal-title":"Pediatr Res"},{"key":"BFsrep03644_CR5","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2174\/138920111795542688","volume":"12","author":"R Giugliani","year":"2011","unstructured":"Giugliani, R., Carvalho, C. G., Herber, S. & de Camargo Pinto, L. L. Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI. Curr Pharm Biotechnol 12, 956\u201362 (2011).","journal-title":"Curr Pharm Biotechnol"},{"key":"BFsrep03644_CR6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/PRM-2012-0194","volume":"5","author":"NR Guarany","year":"2012","unstructured":"Guarany, N. R., Schwartz, I. V., Guarany, F. C. & Giugliani, R. Functional capacity evaluation of patients with mucopolysaccharidosis. J Pediatr Rehabil Med 5, 37\u201346 (2012).","journal-title":"J Pediatr Rehabil Med"},{"key":"BFsrep03644_CR7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","volume":"94","author":"P Harmatz","year":"2008","unstructured":"Harmatz, P. et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 94, 469\u201375 (2008).","journal-title":"Mol Genet Metab"},{"key":"BFsrep03644_CR8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/PRM-2010-0114","volume":"3","author":"A McDonald","year":"2010","unstructured":"McDonald, A., Steiner, R., Kuehl, K. & Turbeville, S. Clinical utility of endurance measures for evaluation of treatment in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr Rehabil Med 3, 119\u201327 (2010).","journal-title":"J Pediatr Rehabil Med"},{"key":"BFsrep03644_CR9","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ajmg.a.35263","volume":"158A","author":"YB Sohn","year":"2012","unstructured":"Sohn, Y. B. et al. Enzyme replacement therapy improves joint motion and outcome of the 12-min walk test in a mucopolysaccharidosis type VI patient previously treated with bone marrow transplantation. Am J Med Genet A 158A, 1158\u201363 (2012).","journal-title":"Am J Med Genet A"},{"key":"BFsrep03644_CR10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ymgme.2007.04.009","volume":"91","author":"D Auclair","year":"2007","unstructured":"Auclair, D., Hopwood, J. J., Lemontt, J. F., Chen, L. & Byers, S. Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI. Mol Genet Metab 91, 352\u201361 (2007).","journal-title":"Mol Genet Metab"},{"key":"BFsrep03644_CR11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/mt.2010.257","volume":"19","author":"G Cotugno","year":"2011","unstructured":"Cotugno, G. et al. Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer. Mol Ther 19, 461\u20139 (2011).","journal-title":"Mol Ther"},{"key":"BFsrep03644_CR12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/hum.2009.189","volume":"21","author":"G Cotugno","year":"2010","unstructured":"Cotugno, G. et al. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Hum Gene Ther 21, 555\u201369 (2010).","journal-title":"Hum Gene Ther"},{"key":"BFsrep03644_CR13","doi-asserted-by":"crossref","first-page":"8214","DOI":"10.1073\/pnas.93.16.8214","volume":"93","author":"M Evers","year":"1996","unstructured":"Evers, M. et al. Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI. Proc Natl Acad Sci U S A 93, 8214\u20139 (1996).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFsrep03644_CR14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/mt.2012.9","volume":"20","author":"KP Ponder","year":"2012","unstructured":"Ponder, K. P. et al. Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats. Mol Ther 20, 898\u2013907 (2012).","journal-title":"Mol Ther"},{"key":"BFsrep03644_CR15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1203\/01.PDR.0000084085.65972.3F","volume":"54","author":"OF Strauch","year":"2003","unstructured":"Strauch, O. F. et al. Cardiac and ocular pathologies in a mouse model of mucopolysaccharidosis type VI. Pediatr Res 54, 701\u20138 (2003).","journal-title":"Pediatr Res"},{"key":"BFsrep03644_CR16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0021-9975(08)80258-7","volume":"109","author":"M Yoshida","year":"1993","unstructured":"Yoshida, M., Ikadai, H., Maekawa, A., Takahashi, M. & Nagase, S. Pathological characteristics of mucopolysaccharidosis VI in the rat. J Comp Pathol 109, 141\u201353 (1993).","journal-title":"J Comp Pathol"},{"key":"BFsrep03644_CR17","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1172\/JCI116268","volume":"91","author":"M Yoshida","year":"1993","unstructured":"Yoshida, M., Noguchi, J., Ikadai, H., Takahashi, M. & Nagase, S. Arylsulfatase B-deficient mucopolysaccharidosis in rats. J Clin Invest 91, 1099\u2013104 (1993).","journal-title":"J Clin Invest"},{"key":"BFsrep03644_CR18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-008-0821-1","volume":"31","author":"MM Sleeper","year":"2008","unstructured":"Sleeper, M. M. et al. Clinical characterization of cardiovascular abnormalities associated with feline mucopolysaccharidosis I and VI. J Inherit Metab Dis 31, 424\u201331 (2008).","journal-title":"J Inherit Metab Dis"},{"key":"BFsrep03644_CR19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bbr.2012.04.051","volume":"233","author":"G Baldo","year":"2012","unstructured":"Baldo, G. et al. Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice. Behav Brain Res 233, 169\u201375 (2012).","journal-title":"Behav Brain Res"},{"key":"BFsrep03644_CR20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00001756-199305000-00011","volume":"4","author":"PL Chang","year":"1993","unstructured":"Chang, P. L., Lambert, D. T. & Pisa, M. A. Behavioral abnormalities in a murine model of a human lysosomal storage disease. Neuroreport 4, 507\u201310 (1993).","journal-title":"Neuroreport"},{"key":"BFsrep03644_CR21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbr.2004.08.019","volume":"158","author":"KM Hemsley","year":"2005","unstructured":"Hemsley, K. M. & Hopwood, J. J. Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA). Behav Brain Res 158, 191\u20139 (2005).","journal-title":"Behav Brain Res"},{"key":"BFsrep03644_CR22","doi-asserted-by":"crossref","first-page":"e25717","DOI":"10.1371\/journal.pone.0025717","volume":"6","author":"A Langford-Smith","year":"2011","unstructured":"Langford-Smith, A. et al. Female mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field test. PLoS One 6, e25717 (2011).","journal-title":"PLoS One"},{"key":"BFsrep03644_CR23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1601-183X.2011.00706.x","volume":"10","author":"A Langford-Smith","year":"2011","unstructured":"Langford-Smith, A. et al. Hyperactive behavior in the mouse model of mucopolysaccharidosis IIIB in the open field and home cage environments. Genes Brain Behav 10, 673\u201382 (2011).","journal-title":"Genes Brain Behav"},{"key":"BFsrep03644_CR24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.brainres.2007.10.036","volume":"1188","author":"D Pan","year":"2008","unstructured":"Pan, D., Sciascia, A., 2nd, Vorhees, C. V. & Williams, M. T. Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome. Brain Res 1188, 241\u201353 (2008).","journal-title":"Brain Res"},{"key":"BFsrep03644_CR25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.brainres.2006.01.008","volume":"1076","author":"GK Reolon","year":"2006","unstructured":"Reolon, G. K. et al. Long-term memory for aversive training is impaired in Idua(\u2212\/\u2212) mice, a genetic model of mucopolysaccharidosis type I. Brain Res 1076, 225\u201330 (2006).","journal-title":"Brain Res"},{"key":"BFsrep03644_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2006.05.079","volume":"1104","author":"AC Crawley","year":"2006","unstructured":"Crawley, A. C. et al. Characterization of a C57BL\/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Brain Res 1104, 1\u201317 (2006).","journal-title":"Brain Res"},{"key":"BFsrep03644_CR27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cne.21847","volume":"511","author":"FW Lischka","year":"2008","unstructured":"Lischka, F. W. et al. Altered olfactory epithelial structure and function in feline models of mucopolysaccharidoses I and VI. J Comp Neurol 511, 360\u201372 (2008).","journal-title":"J Comp Neurol"},{"key":"BFsrep03644_CR28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1755-8417-2-4","volume":"2","author":"A Tessitore","year":"2009","unstructured":"Tessitore, A., Pirozzi, M. & Auricchio, A. Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI. Pathogenetics 2, 4 (2009).","journal-title":"Pathogenetics"},{"key":"BFsrep03644_CR29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2004.01.015","volume":"82","author":"RL Mango","year":"2004","unstructured":"Mango, R. L. et al. Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol Genet Metab 82, 4\u201319 (2004).","journal-title":"Mol Genet Metab"},{"key":"BFsrep03644_CR30","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1172\/JCI118617","volume":"97","author":"AC Crawley","year":"1996","unstructured":"Crawley, A. C. et al. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest 97, 1864\u201373 (1996).","journal-title":"J Clin Invest"},{"key":"BFsrep03644_CR31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/PRM-2010-0105","volume":"3","author":"EB Fung","year":"2010","unstructured":"Fung, E. B., Johnson, J. A., Madden, J., Kim, T. & Harmatz, P. Bone density assessment in patients with mucopolysaccharidosis: A preliminary report from patients with MPS II and VI. J Pediatr Rehabil Med 3, 13\u201323 (2010).","journal-title":"J Pediatr Rehabil Med"},{"key":"BFsrep03644_CR32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/PRM-2010-0108","volume":"3","author":"P Garcia","year":"2010","unstructured":"Garcia, P. et al. Skeletal complications in mucopolysaccharidosis VI patients: Case reports. J Pediatr Rehabil Med 3, 63\u20139 (2010).","journal-title":"J Pediatr Rehabil Med"},{"key":"BFsrep03644_CR33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0925-4439(95)00070-4","volume":"1272","author":"CM Simonaro","year":"1995","unstructured":"Simonaro, C. M. & Schuchman, E. H. N-acetylgalactosamine-4-sulfatase: identification of four new mutations within the conserved sulfatase region causing mucopolysaccharidosis type VI. Biochim Biophys Acta 1272, 129\u201332 (1995).","journal-title":"Biochim Biophys Acta"},{"key":"BFsrep03644_CR34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pain.2009.06.006","volume":"145","author":"MK Boettger","year":"2009","unstructured":"Boettger, M. K. et al. Gait abnormalities differentially indicate pain or structural joint damage in monoarticular antigen-induced arthritis. Pain 145, 142\u201350 (2009).","journal-title":"Pain"},{"key":"BFsrep03644_CR35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vascn.2011.10.002","volume":"65","author":"H Nagase","year":"2012","unstructured":"Nagase, H., Kumakura, S. & Shimada, K. Establishment of a novel objective and quantitative method to assess pain-related behavior in monosodium iodoacetate-induced osteoarthritis in rat knee. J Pharmacol Toxicol Methods 65, 29\u201336 (2012).","journal-title":"J Pharmacol Toxicol Methods"},{"key":"BFsrep03644_CR36","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1371\/journal.pone.0000772","volume":"2","author":"CD Heldermon","year":"2007","unstructured":"Heldermon, C. D. et al. Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS One 2, e772 (2007).","journal-title":"PLoS One"},{"key":"BFsrep03644_CR37","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/mt.2010.299","volume":"19","author":"C Spampanato","year":"2011","unstructured":"Spampanato, C. et al. Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. Mol Ther 19, 860\u20139 (2011).","journal-title":"Mol Ther"},{"key":"BFsrep03644_CR38","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"P Harmatz","year":"2005","unstructured":"Harmatz, P. et al. Direct comparison of measures of endurance, mobility and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115, e681\u20139 (2005).","journal-title":"Pediatrics"},{"key":"BFsrep03644_CR39","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10545-012-9474-1","volume":"35","author":"A Thumler","year":"2012","unstructured":"Thumler, A. et al. Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series. J Inherit Metab Dis 35, 1071\u20139 (2012).","journal-title":"J Inherit Metab Dis"},{"key":"BFsrep03644_CR40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1590\/S0021-75572008000200007","volume":"84","author":"A Cardoso-Santos","year":"2008","unstructured":"Cardoso-Santos, A. et al. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): assessment of joint mobility and grip and pinch strength. J Pediatr (Rio J) 84, 130\u20135 (2008).","journal-title":"J Pediatr (Rio J)"},{"key":"BFsrep03644_CR41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0304-3959(00)00402-4","volume":"90","author":"KE Abraham","year":"2001","unstructured":"Abraham, K. E., McGinty, J. F. & Brewer, K. L. Spinal and supraspinal changes in opioid mRNA expression are related to the onset of pain behaviors following excitotoxic spinal cord injury. Pain 90, 181\u201390 (2001).","journal-title":"Pain"},{"key":"BFsrep03644_CR42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0006-8993(95)01106-4","volume":"704","author":"I Bileviciute","year":"1995","unstructured":"Bileviciute, I., Stenfors, C., Theodorsson, E., Beckman, M. & Lundeberg, T. Significant changes in neuropeptide concentrations in the brain of normotensive (WKY) and spontaneously hypertensive (SHR) rats following knee joint monoarthritis. Brain Res 704, 71\u20138 (1995).","journal-title":"Brain Res"},{"key":"BFsrep03644_CR43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pain.2006.03.010","volume":"124","author":"Y Hong","year":"2006","unstructured":"Hong, Y., Ji, H. & Wei, H. Topical ketanserin attenuates hyperalgesia and inflammation in arthritis in rats. Pain 124, 27\u201333 (2006).","journal-title":"Pain"},{"key":"BFsrep03644_CR44","doi-asserted-by":"crossref","first-page":"e23083","DOI":"10.1371\/journal.pone.0023083","volume":"6","author":"S Lolignier","year":"2011","unstructured":"Lolignier, S. et al. Nav1.9 channel contributes to mechanical and heat pain hypersensitivity induced by subacute and chronic inflammation. PLoS One 6, e23083 (2011).","journal-title":"PLoS One"},{"key":"BFsrep03644_CR45","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.bjp.0701044","volume":"120","author":"KA Sluka","year":"1997","unstructured":"Sluka, K. A., Milton, M. A., Willis, W. D. & Westlund, K. N. Differential roles of neurokinin 1 and neurokinin 2 receptors in the development and maintenance of heat hyperalgesia induced by acute inflammation. Br J Pharmacol 120, 1263\u201373 (1997).","journal-title":"Br J Pharmacol"},{"key":"BFsrep03644_CR46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0304-3959(87)90186-2","volume":"29","author":"M De Castro-Costa","year":"1987","unstructured":"De Castro-Costa, M., Gybels, J., Kupers, R. & Van Hees, J. Scratching behavior in arthritic rats: a sign of chronic pain or itch? Pain 29, 123\u201331 (1987).","journal-title":"Pain"},{"issue":"7","key":"BFsrep03644_CR47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1590\/S0100-879X2012007500072","volume":"45","author":"R.M. Castilhos","year":"2012","unstructured":"Castilhos, R. M. et al. Severity score system for progressive myelopathy: development and validation of a new clinical scale. Braz J Med Biol Res 45, 565\u201372.","journal-title":"Brazilian Journal of Medical and Biological Research"},{"key":"BFsrep03644_CR48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ymgme.2012.07.018","volume":"107","author":"GA Solanki","year":"2012","unstructured":"Solanki, G. A. et al. A multinational, multidisciplinary consensus for the diagnosis and management of spinal cord compression among patients with mucopolysaccharidosis VI. Mol Genet Metab 107, 15\u201324 (2012).","journal-title":"Mol Genet Metab"},{"key":"BFsrep03644_CR49","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00431-008-0910-z","volume":"168","author":"M Scarpa","year":"2009","unstructured":"Scarpa, M. et al. Mucopolysaccharidosis VI: the Italian experience. Eur J Pediatr 168, 1203\u20136 (2009).","journal-title":"Eur J Pediatr"},{"key":"BFsrep03644_CR50","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1006\/geno.1995.9962","volume":"29","author":"T Kunieda","year":"1995","unstructured":"Kunieda, T. et al. Mucopolysaccharidosis type VI in rats: isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene and identification of the mutation. Genomics 29, 582\u20137 (1995).","journal-title":"Genomics"},{"key":"BFsrep03644_CR51","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.mt.6300325","volume":"16","author":"A Tessitore","year":"2008","unstructured":"Tessitore, A. et al. Biochemical, pathological and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle. Mol Ther 16, 30\u20137 (2008).","journal-title":"Mol Ther"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep03644.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep03644","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep03644.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T08:33:18Z","timestamp":1672993998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep03644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,17]]}},"alternative-id":["BFsrep03644"],"URL":"https:\/\/doi.org\/10.1038\/srep03644","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,10]]},"assertion":[{"value":"30 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The corresponding author is responsible for submitting a competing financial interests statement on behalf of all authors of the paper. There is no competing financial interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3644"}}